Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CKS1B | P61024 | 3/20 | 0.35 |
| ▸ | SKP1 | P63208 | 3/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545114 | 0.82 | CNR1 (0.69) | CNR1CNR2PTPN11CKS1BSKP1 | |
| SCHEMBL4789263 | 0.82 | ADRA1D (0.40) | CNR1CNR2ADRA1DADRA1AADRA1B | |
| SCHEMBL4749104 | 0.81 | CNR1 (0.56) | CNR1CNR2ADRA1DADRA1AADRA1B | |
| SCHEMBL14545104 | 0.76 | CNR1 (0.44) | CNR1CNR2ADRA1DADRA1AADRA1B | |
| SCHEMBL4693209 | 0.74 | MEN1 (0.47) | ADRA1DADRA1AADRA1BALDH1A1L3MBTL1 | |
| SCHEMBL3439989 | 0.68 | L3MBTL1 (0.47) | ADRA1DADRA1AADRA1BALDH1A1L3MBTL1 | |
| SCHEMBL3194921 | 0.67 | ALDH1A1 (0.52) | ADRA1DADRA1AADRA1BALDH1A1L3MBTL1 | |
| SCHEMBL14545642 | 0.66 | CNR1 (0.59) | CNR1CNR2PTPN11CKS1BSKP1 | |
| SCHEMBL14545541 | 0.65 | CNR1 (0.55) | CNR1CNR2PTPN11CKS1BSKP1 | |
| SCHEMBL14544990 | 0.65 | CNR1 (0.59) | CNR1CNR2CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871762-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006113704-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885ADRA1D 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.